摘要
目的:分析布地奈德治疗COPD的效果及其对炎性标志物的影响。方法:2017年8月-2019年8月收治COPD患者200例,分为四组。观察1组给予沙丁胺醇雾化吸入;观察2组给予沙丁胺醇+布地奈德2 mg雾化吸入;观察3组给予沙丁胺醇+布地奈德4 mg雾化吸入;观察4组给予沙丁胺醇+布地奈德8 mg雾化吸入;另选择健康者40例作为对照组。比较各组疗效及相关指标水平。结果:观察2组、观察3组及观察4组治疗第5天、第7天、第10天时血氧饱和度明显高于观察1组;观察2组、观察3组、观察4组治疗后第5天、第10天症状评分低于观察1组,且观察4组最低;观察2、3、4组治疗总有效率高于观察1组,差异均有统计学意义(P<0.05)。COPD患者急性加重期与缓解期CD4+、C反应蛋白及超敏C反应蛋白水平和对照组比较,差异有统计学意义(P<0.05)。结论:布地奈德治疗COPD有效,可减轻炎性反应。
Objective:To analyze the effect of budesonide on COPD and its impact on inflammatory markers.Methods:From August 2017 to August 2019,200 patients with COPD were selected,they were divided into the four groups.The observation group 1 was given inhalation of salbutamol;The observation group 2 was given inhalation of salbutamol and budesonide 2mg;The observation group 3 was given inhalation of salbutamol and budesonide 4 mg;The observation group 4 was given inhalation of salbutamol and budesonide 8mg.In addition,40 healthy persons were selected as the control group.We compared the efficacy and related index levels of each group.Results:The blood oxygen saturation of the observation group 2,the observation group 3 and the observation group 4 was significantly higher than that of the observation group 1 on the 5th,7th and 10th day of treatment,the symptom score of the observation group 2,the observation group 3 and the observation group 4 on the 5th and 10th day after treatment was lower than that of observation group 1,and the observation group 4 was the lowest.The total effective rate of observation group 2,3 and 4 was higher than that of observation group 1,the differences were statistically significant(P<0.05).The levels of CD4+,C-reactive protein and hypersensitive C-reactive protein in patients with COPD in acute exacerbation and remission were significantly higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Budesonide is effective in the treatment of COPD and can reduce inflammatory reaction.
作者
刘雨田
吕德
李月琼
Liu Yutian;Lv De;Li Yueqiong(The Fourth Department of Internal Medicine,Peng Pai Memorial Hospital of Haifeng County,Shanwei City,Guangdong Haifeng 516400)
出处
《中国社区医师》
2020年第24期116-118,共3页
Chinese Community Doctors
基金
2017年度汕尾市科技计划项目(项目编号:17C017)。
关键词
布地奈德
慢性阻塞性肺疾病
炎性标志物
影响
Budesonide
Chronic obstructive pulmonary disease
Inflammatory markers
Influence